Bajaj Healthcare Limited (BHL), one of the leading manufacturers of API and formulations, has announced that it has received FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug and formulation for its tablets. Hydroxychloroquine Sulphate has been recommended by several countries, including the US, with limited dosage for Covid-19 patients and as a- preventive for high-risk…